Completed
A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors
NCT02549937
- Conditions
- Adenocarcinoma, Carcinoid Tumor, Carcinoma, +12 more
- Locations
-
- City of Hope Comprehensive Cancer Center Los Angeles, California, United States
- Rocky Mountain Cancer Center Denver, Colorado, United States
- SCRI at HealthONE Denver, Colorado, United States
- Florida Cancer Specialists Sarasota, Florida, United States